Compare VPG & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VPG | ESPR |
|---|---|---|
| Founded | 2009 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 715.7M | 793.7M |
| IPO Year | 2010 | 2013 |
| Metric | VPG | ESPR |
|---|---|---|
| Price | $43.44 | $3.04 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $53.50 | $8.25 |
| AVG Volume (30 Days) | 283.4K | ★ 3.4M |
| Earning Date | 01-01-0001 | 04-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 86.21 |
| EPS | ★ 0.40 | N/A |
| Revenue | $307,202,000.00 | ★ $332,314,000.00 |
| Revenue This Year | $7.21 | $27.35 |
| Revenue Next Year | $6.92 | N/A |
| P/E Ratio | $108.25 | ★ N/A |
| Revenue Growth | 0.22 | ★ 185.66 |
| 52 Week Low | $18.57 | $0.73 |
| 52 Week High | $56.25 | $4.18 |
| Indicator | VPG | ESPR |
|---|---|---|
| Relative Strength Index (RSI) | 41.96 | 41.62 |
| Support Level | $37.61 | $2.36 |
| Resistance Level | $49.72 | $3.02 |
| Average True Range (ATR) | 2.78 | 0.17 |
| MACD | -0.68 | -0.06 |
| Stochastic Oscillator | 25.95 | 34.93 |
Vishay Precision Group Inc manufactures and markets sensors, and sensor-based measurement systems, as well as specialty resistors and strain gages based on proprietary technology. The company provides precision products and solutions, many of which are designed-in by customers, specializing in the growing markets of stress, force, weight, pressure, and current measurements. The company reports in three product segments: Sensors segment, Weighing Solutions segment, and Measurement Systems segment. It has a business presence in the United States and other countries. It generates the maximum of its revenue from the United States.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.